Since the peripherally selective CB1 antagonist TM38837 was reported to elicit minimal CNS effects in humans [478], peripheral CB1R blockade may well be a viable therapeutic option for targeting metabolic disorders. The gene discussed is CNR1; the disease is metabolic disease.